FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						OCCU	011 00(11)	ח נווכ	ilivesilileli		ilpariy Act	01 10-10								
Name and Address of Reporting Person* Podnos Yale					2. Issuer Name and Ticker or Trading Symbol Oncology Institute, Inc. [TOI]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last)	,	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/17/2023									Officer below)	(give title	lical (Other (s below)		
18000 STUDEBAKER RD, SUITE 800					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	os c	A	90703)		led by Mor	•	orting Persor n One Repor		
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to														
									defense co							ir or writterr	piair tii	at is interiord	10	
		Tab	ole I - Nor	n-Deriv	ative	e Se	curities	s Ac	quired,	Dis	posed c	of, or Be	enef	icially	/ Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Code (I	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)					es For ally (D) following (I) (Form (D) o	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
										v	Amount	ount (A) or (D)		Price	Reported Transact (Instr. 3	ion(s)		(Instr. 4)		
Common stock 03/17/					7/202	3			A		33,219) (1) A		\$0	\$0 90,466			D		
		-	Table II -						uired, D , option						Owned					
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution ecurity or Exercise (Month/Day/Year) if any		3A. Deemed Execution I if any (Month/Day	Date, Transaction Code (Instr.			n of l		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	ily	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of	nount imber ares						
Non- Qualified Stock Option (right to	\$ 0.481	03/17/2023			Α		83,047		(2)	0	03/17/2033	Common	83	3,047	\$0	83,047	7	D		

Explanation of Responses:

- 1. Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.
- 2. The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

Remarks:

/s/ Mark Hueppelsheuser,

03/21/2023 Attorney-in-Fact for Yale

Podnos

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.